13F Data
13F filer · CIK 1457494

Delphi Management Partners VIII, L.L.C.

San Mateo, CA · filing since Q4 2019 · last filing Nov 15, 2021
Reported value
$138.5M
+$11.8M vs prior
Positions
4
New / sold out
0 / 0
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $0
Top-10 weight
100.0%

Biggest buys vs Q2 2021

No new or increased positions this quarter.

Biggest sells vs Q2 2021

No reduced or sold positions this quarter.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2019: $126.7MQ4 2020: $152.1MQ1 2021: $144.8MQ2 2021: $126.6MQ3 2021: $138.5M
Q4 2019Q3 2021

Holdings · Q3 2021

#SecuritySharesValueWeight
1Tandem Diabetes, Inc.COMMON STOCK1,000,000$119.4M86.22%
2Karyopharm Therapeutics, Inc.COMMON STOCK2,263,006$13.2M9.51%
3Calithera Biosciences, Inc.COMMON STOCK2,426,702$5.3M3.82%
4Mereo BioPharma Group PLCADS256,734$621.0K0.45%